Abstract
Despite good results in reducing in-stent restenosis during cardiac stenting procedures, a number of issues in the application of drug-eluting stents still challenge the industry. These include drug-elution kinetics and long-term biocompatibility. Some of the latest developments in these areas are described here.
MeSH terms
-
Animals
-
Anti-Inflammatory Agents / administration & dosage*
-
Blood Vessel Prosthesis / adverse effects*
-
Coated Materials, Biocompatible / administration & dosage*
-
Coated Materials, Biocompatible / chemistry
-
Drug Implants / administration & dosage*
-
Drug Implants / chemistry
-
Graft Occlusion, Vascular / etiology*
-
Graft Occlusion, Vascular / prevention & control*
-
Humans
-
Stents / adverse effects*
-
Surface Properties
Substances
-
Anti-Inflammatory Agents
-
Coated Materials, Biocompatible
-
Drug Implants